JP2023516677A - ペプチド及び医薬組成物による炎症性疾患の治療 - Google Patents

ペプチド及び医薬組成物による炎症性疾患の治療 Download PDF

Info

Publication number
JP2023516677A
JP2023516677A JP2022552799A JP2022552799A JP2023516677A JP 2023516677 A JP2023516677 A JP 2023516677A JP 2022552799 A JP2022552799 A JP 2022552799A JP 2022552799 A JP2022552799 A JP 2022552799A JP 2023516677 A JP2023516677 A JP 2023516677A
Authority
JP
Japan
Prior art keywords
yde
gly
compound
formula
leu
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022552799A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023516677A5 (https=
Inventor
ユー，ウォンサン
パク，ラリー，チョン
Original Assignee
ユーユー ファーマ，インコーポレーテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ユーユー ファーマ，インコーポレーテッド filed Critical ユーユー ファーマ，インコーポレーテッド
Publication of JP2023516677A publication Critical patent/JP2023516677A/ja
Publication of JP2023516677A5 publication Critical patent/JP2023516677A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
JP2022552799A 2020-03-05 2021-03-05 ペプチド及び医薬組成物による炎症性疾患の治療 Pending JP2023516677A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202062985603P 2020-03-05 2020-03-05
US62/985,603 2020-03-05
PCT/IB2021/000423 WO2021191689A2 (en) 2020-03-05 2021-03-05 Treatment of inflammatory diseases with peptides and pharmaceutical compositions

Publications (2)

Publication Number Publication Date
JP2023516677A true JP2023516677A (ja) 2023-04-20
JP2023516677A5 JP2023516677A5 (https=) 2024-04-04

Family

ID=77890982

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022552799A Pending JP2023516677A (ja) 2020-03-05 2021-03-05 ペプチド及び医薬組成物による炎症性疾患の治療

Country Status (7)

Country Link
US (1) US20230146455A1 (https=)
EP (1) EP4114430A4 (https=)
JP (1) JP2023516677A (https=)
KR (1) KR20220149745A (https=)
CA (1) CA3170606A1 (https=)
TW (1) TW202146426A (https=)
WO (1) WO2021191689A2 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2766160C2 (ru) 2017-05-17 2022-02-08 Юю Фарма, Инк. Новый пептид и фармацевтический состав для лечения глазного заболевания, содержащий пептид в качестве активного фармацевтического ингредиента
US11613558B2 (en) 2018-11-14 2023-03-28 Yuyu Pharma, Inc. Peptides and pharmaceutical compositions for treating eye diseases
WO2023081445A1 (en) 2021-11-08 2023-05-11 FFDW Corp. Urine quantifying bed pad
EP4450079A4 (en) * 2021-12-13 2025-12-10 Eyebiokorea Inc COMPOSITION FOR THE TREATMENT OF MACULAR DEGENERATION COMPRISING A NEW PEPTIDE
WO2025149851A2 (en) * 2024-01-12 2025-07-17 Yuyu Pharma, Inc. Methods for treating inflammatory diseases
WO2026049571A1 (ko) * 2024-08-29 2026-03-05 루다큐어 주식회사 통증 치료용 조성물

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011517659A (ja) * 2008-01-09 2011-06-16 ザ スキーペンズ アイ リサーチ インスティチュート インコーポレイテッド 眼の炎症性障害を処置するための治療組成物
WO2020099925A2 (en) * 2018-11-14 2020-05-22 Yuyu Pharma, Inc. Peptides and pharmaceutical compositions for treating eye diseases
JP2020520372A (ja) * 2017-05-17 2020-07-09 ユーユー ファーマ，インコーポレーテッド 新規ペプチド及びその新規ペプチドを活性成分として含む眼疾患の治療のための医薬組成物

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6037135A (en) * 1992-08-07 2000-03-14 Epimmune Inc. Methods for making HLA binding peptides and their uses
EP3539559B1 (en) * 2016-04-08 2020-08-26 Eyebio Korea Collagen type ii alpha-1-based peptide for use in the treatment of macular degeneration
KR101795653B1 (ko) * 2016-05-19 2017-11-09 인제대학교 산학협력단 콜라겐 타입 ii 펩타이드-아플리버셉트의 키메라 단백질을 유효성분으로 함유하는 혈관신생 억제용 조성물
KR20180074928A (ko) * 2016-12-26 2018-07-04 주식회사 아이바이오코리아 건성안 예방 또는 치료용 동물 의약품 조성물

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011517659A (ja) * 2008-01-09 2011-06-16 ザ スキーペンズ アイ リサーチ インスティチュート インコーポレイテッド 眼の炎症性障害を処置するための治療組成物
JP2020520372A (ja) * 2017-05-17 2020-07-09 ユーユー ファーマ，インコーポレーテッド 新規ペプチド及びその新規ペプチドを活性成分として含む眼疾患の治療のための医薬組成物
WO2020099925A2 (en) * 2018-11-14 2020-05-22 Yuyu Pharma, Inc. Peptides and pharmaceutical compositions for treating eye diseases

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
CORNEA, vol. 28, no. 9, JPN6025017487, 2009, pages 1023 - 1027, ISSN: 0005737788 *
日大医誌, vol. 75, no. 1, JPN6025017488, 2016, pages 52 - 53, ISSN: 0005737787 *

Also Published As

Publication number Publication date
WO2021191689A3 (en) 2021-12-23
US20230146455A1 (en) 2023-05-11
EP4114430A4 (en) 2025-05-14
CA3170606A1 (en) 2021-09-30
EP4114430A2 (en) 2023-01-11
TW202146426A (zh) 2021-12-16
KR20220149745A (ko) 2022-11-08
WO2021191689A2 (en) 2021-09-30

Similar Documents

Publication Publication Date Title
JP2023516677A (ja) ペプチド及び医薬組成物による炎症性疾患の治療
US11820775B2 (en) Pyrrolopyrimidine ITK inhibitors
US9844550B2 (en) Phtalazinone derivatives and manufacturing process thereof
JP7522732B2 (ja) 眼疾患治療用のペプチド及び医薬組成物
US20200354343A1 (en) Heterocyclic inhibitors of tyrosine kinase
CN107635404A (zh) 用于治疗疾病的mct4抑制剂
JP2020520372A (ja) 新規ペプチド及びその新規ペプチドを活性成分として含む眼疾患の治療のための医薬組成物
CN113045551A (zh) 一种作为甲状腺激素β受体激动剂的化合物及其用途
US20230017597A1 (en) 8-substituted styryl xanthine derivatives and uses thereof
US20220194940A1 (en) Heterocyclic inhibitors of tyrosine kinase
WO2021027647A1 (zh) 桥杂环基取代的嘧啶类化合物及其制备方法和医药用途
JP7834361B2 (ja) 置換４－（［１，２，４］トリアゾロ［１，５－ａ］ピリジン－６－イル）チオフェン－２－カルボキサミド誘導体及びその使用
CN111072675A (zh) 含氮稠合三环衍生物及其用途
CN111018856A (zh) 8-取代的苯乙烯基黄嘌呤衍生物及其用途
WO2026017806A1 (en) Triazolo compounds for use in the treatment of graft-versus-host disease
TW202227419A (zh) 橋雜環基取代的嘧啶類化合物及其製備方法和醫藥用途
HK40093954A (en) Substituted 4‑([1,2,4]triazolo[1,5‑a]pyridin‑6‑yl)thiophene‑2‑carboxamide derivatives and use thereof
HK40093954B (en) Substituted 4‑([1,2,4]triazolo[1,5‑a]pyridin‑6‑yl)thiophene‑2‑carboxamide derivatives and use thereof
AU2024355253A1 (en) Withaferin a analog and method for treatment using the same
JP2018080155A (ja) Ｂｃａｔ１阻害剤を使用する組成物及び治療方法

Legal Events

Date Code Title Description
RD01 Notification of change of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7426

Effective date: 20230721

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20230721

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240304

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240304

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20240325

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250507

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250807

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20251125

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260225